UMIN ID: UMIN000000482
Registered date:01/09/2006
A phase II study for anaplastic thyroid cancer
Basic Information
| Recruitment status | |
|---|---|
| Health condition(s) or Problem(s) studied | anaplastic thyroid cancer |
| Date of first enrollment | 2006/09/01 |
| Target sample size | 20 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | docetaxelat 60 mg/m2 The interval is 3 weeks |
Outcome(s)
| Primary Outcome | Response rate |
|---|---|
| Secondary Outcome | The median survival and side effects |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | heavy thoracic, abdominal, or pericardial dropsy; heavy complications such as myocarial infarction, heat failure, cerebral infarctio within 6 months; uncontrolled diabetes; uncontrolled hypertension;symptomatic brain metastases; |
Related Information
| Primary Sponsor | Nagoya university hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | None |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Kenji Kawada |
| Address | 65 Tsurumai, Showa Nagoya Japan |
| Telephone | 052-744-1903 |
| Affiliation | Nagoya university hospital Clinical oncology and chemotherapy |
| scientific contact | |
| Name | Yuichi Ando |
| Address | 65 Tsurumai, Showa Nagoya Japan |
| Telephone | 052-744-1903 |
| Affiliation | Nagoya university hospital Clinical oncology and chemotherapy |